Adaptive Biotechnologies Corp vs Advanced Drainage Systems Inc — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.05B), while Advanced Drainage Systems Inc trades at $143.7 (market cap $10.68B). The key difference: Advanced Drainage Systems Inc is far larger — about 2.6× Adaptive Biotechnologies Corp's market cap, and Advanced Drainage Systems Inc pays a 0.56% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WMS | |
|---|---|---|
Market Cap | $4.05B | $10.68B |
Sector | Health | Industrials |
52-Week High | $25.45 | $175.38 |
52-Week Low | $12.30 | $129.50 |
Enterprise Value | $4.12B | $12.29B |
Dividend Yield | — | 0.56% |
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
Advanced Drainage Systems (WMS) trades at $143.95, down 3.03% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings of $2.49 per share, beating estimates, and maintains solid profitability with a 14% net income margin and 24.9% ROE. Recent news highlights Q1 fiscal 2027 sales growth of 21% and consistent dividend payments, though cash flow turned negative in 2025 due to increased investing activity.
The outlook is mixed; analyst consensus is a Buy with a $185.86 price target, but near-term risks include volatile cash flows and high valuation multiples. Upside potential hinges on execution of growth initiatives and infrastructure demand, while margin pressure and economic sensitivity pose challenges.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Advanced Drainage Systems Inc is engaged in designing, manufacturing, and marketing thermoplastic corrugated pipe and related water management products in North and South America, and Europe. The company's operating segment includes Pipe
Read more on WMS →